



Aurobindo Pharma Announces Licensing and Supply Agreement with Pfizer for Supply of Finished Dosage Products

Hyderabad, India. (March 3rd, 2009) – Aurobindo Pharma is pleased to announce that it has expanded its partnership further by executing licensing and Supply agreements for several Solid Dosage and Sterile products with Pfizer Inc., a global leader in Pharmaceuticals.

The agreement allows access to Pfizer's newly formed Established Product Business Unit to exploit the sales potential for these post Loss of Exclusivity (LOE) products through its global commercial presence. Aurobindo has a large manufacturing base approved by several Regulatory Authorities with strong product portfolio for the manufacture of post LOE products. The partnership alliance is mutually beneficial.

"We initiated our partnership with a few products. The execution of these agreements will pave the way for further strengthening our partnership and will accelerate Pfizer's strategy for expanding our Established Products portfolio" said Mr. David Simmons, President and General Manager, Pfizer Established Product Business Unit.

"We look forward to working with Aurobindo and are delighted that they are able to contribute towards our strategy both on Solids, Steriles and Product Reformulations" said Mr. Kelvin Cooper, Senior Vice President, Portfolio Devolvement, Establish Product Business Unit.

Commenting on the alliance, Mr.P.V.Ramprasad Reddy, Chairman, Aurobindo Pharma said "It is an exciting opportunity for Aurobindo and provides for stability towards company's earnings and accelerate its growth plans. The current agreements are targeted towards US and European markets and will continue to explore ways to further extend this partnership"

About Aurobindo:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries.

About Pfizer:

Pfizer Inc, founded in 1849, is dedicated to better health and greater access to health care for people and their valued animals. Every day, approximately 90,000 colleagues in more than 150 countries work to discover, develop, manufacture and deliver quality, safe and effective prescription medicines to patients.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com